pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Incidence and hazard of cancer in patients with T2DM on antidiabetic monotherapy

 GroupsPatients (n) Patient years(PY)Incidence, n (%) Incidence rate/100PYsUnadjusted HR (95% CI)Adjusted HR (95% CI)
Sulfonylurea3225696 (21.58%)Reference, 1Reference,1
12,692.435.48/100 PYs
Metformin5825740 (12.70%)0.82 (0.74-0.91)*0.74 (0.66-0.83)**
13,577.785.45/100 PYs
Others504107 (21.23%)1.44 (1.18-1.77)***1.05 (0.85-1.29)
1,257.818.51/100 PYs

Note:

p = 0.0002.

p < 0.0001.

p = 0.0005. Multivariable Cox’s regression model depicting HRs adjusted for age, sex, CCI, hyperlipidemia, hypertension, pancreatitis, morbid obesity, alcohol use disorders, smoking-related diagnoses, and duration of follow-up.

Korean J Clin Pharm 2019;29:186-92 https://doi.org/10.24304/kjcp.2019.29.3.186
© 2019 Korean J Clin Pharm